Targeting A Key Actor In The Spread Of Triple Negative Breast Cancer
This article was originally published in Start Up
Researchers have identified a molecule found in primary tumors whose suppression leads to metastasis of cancer cells to the lung and lymph nodes. Their findings, which dovetail nicely with clinical research efforts at several companies, could quickly lead to testing of drugs to treat triple negative breast cancer, which has the worst outcome among breast cancer patients due to the high incidence of recurrence and metastatic spread.
You may also be interested in...
Two recent papers looking at very different enzymatic activities illustrate how the study of mutation-based alterations in epigenetic mechanisms, and the multiple complex ways in which these alterations reprogram tumor cells, are rapidly advancing both oncology clinical practice and drug development. One identifies a biomarker that would signal the need for aggressive initial leukemia therapy while the other clarifies the mechanism of a drug target in lymphoma.
Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology replete with novel, interesting targets and broad therapeutic potential. The two companies have adopted similar and until now stealthy strategies, aimed at parlaying a platform of novel products into a quick and lucrative exit.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.